Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
69.00    0.50 (0.73%)
Bid:
68.00
Ask:
70.00
Spread: 2.00 (2.941%)
Market Cap: £314.03m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

7 Jan 2008 10:50

Avacta Group plc

Strategic Alliance

Broader service offering augments market position

Avacta Group plc ("Avacta"), which provides novel detection and analysis technology for the pharmaceutical, defence & security and clinical diagnostics markets, announces an agreement with Agenda 1 Analytical Services Ltd ("Agenda 1").

Agenda 1 provides a wide range of analytical techniques and services from bespoke laboratories located close to Avacta in Bradford, UK. Agenda 1 provides a complementary service offering to Avacta by focusing on small molecule therapeutics, whereas Avacta's strength is in the provision of expert analysis to companies developing large molecule biopharmaceuticals. Consequently, the agreement provides an immediate synergy allowing Avacta to offer an enhanced analytical service to a much wider base of pharmaceutical companies along with access to expertise, resources and technology not available in-house.

The Directors of Avacta believe that this enhanced product offering will enable accelerated growth of the analytical services business because it affords Avacta the ability to offer a greater range of the services required by the pharmaceutical industry. There will be no consideration payable by Avacta for this sharing of services.

Professor Alastair Smith, Chief Executive Officer, Commented:

"Avacta Analytical Limited, Avacta's technical services subsidiary, has made very good progress in its provision of analytical services to the biopharmaceutical sector but we are aware that some potential clients require an even broader range of services than we have been able to offer to date. Today's agreement allows us to extend our services and cover a greater range of the pharmaceutical industry's requirements and my expectation is that this will lead to more rapid growth in the services business of the Group."

7 January 2008Enquiries:Avacta Group plc Tel: 0870 835 4367 Russell Hodgetts Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk WH Ireland Ltd (Nominated Adviser) Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7562 4700 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes.

A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

About Agenda 1

Agenda 1 grew from the analytical laboratories of Nektar Therapeutics (UK) Ltd - (a.k.a. Bradford Particle Design Ltd). The team was formed to utilise their experience as a development group supporting both new technologies and new pharmaceutical products working from early stage project initiation up to and including enabling the release of material for clinical trials.

Agenda 1's client base ranges from major pharmaceutical companies through to virtual companies, and emerging and growing Bio-Pharma businesses. Agenda 1 has developed a number of flexible approaches to help clients access their lab facilities. These include the option to place contract staff into the laboratories via a unique structure with Synergy Outsourcing, a company specialising in scientific personnel. Agenda 1 has also recently launched an innovative "Lab Time-Share" approach, which saw the company awarded the prestigious Royal Society of Chemistry "SME of the month" award for July 2007.

AVACTA GROUP PLC
Date   Source Headline
17th Oct 20137:00 amRNSFirst therapeutic licensing agreement for Affimers
26th Sep 20137:00 amRNSLaunch of Sensipod - First Point of Care Test
18th Sep 20137:00 amRNSIssue of Equity and Notice of Preliminary Results
16th Sep 20137:00 amRNSNew Head of R&D Joins Avacta
2nd Sep 20135:47 pmRNSTR-1 Notification of Major Interest in Shares
29th Aug 20137:00 amRNSPre-close trading update
28th Aug 20137:00 amRNSIssue of Equity
9th Aug 20138:35 amRNSTR-1: Notification of Major Interest in Shares
7th Aug 20135:51 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:31 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:30 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:00 pmRNSTR-1: Notification of Major Interest in Shares
5th Aug 201311:00 amRNSResult of General Meeting
5th Aug 20137:00 amRNSAppointment of a Non-Executive Director
25th Jul 20137:00 amRNSExpansion of Collaboration with ForteBio
18th Jul 20137:00 amRNSConditional Placing to Raise £4.7 Million
23rd May 20138:40 amRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Results
23rd Apr 20137:01 amRNSNotice of Interim Results
23rd Apr 20137:00 amRNSAppointment of Nominated Advisor and Broker
27th Feb 20137:00 amRNSInterest in Affimer Technology
27th Feb 20137:00 amRNSBusiness Update
18th Feb 20135:08 pmRNSAdditional Listing
25th Jan 20132:34 pmRNSResult of AGM
21st Jan 20131:20 pmRNSHolding(s) in Company
7th Jan 20133:47 pmRNSHolding(s) in Company
23rd Oct 20127:00 amRNSPreliminary Results
24th Sep 20127:00 amRNSAvacta and Pall extend Optim distribution to India
13th Sep 201210:24 amRNSNotice of Preliminary Results
24th Aug 20127:00 amRNSPre-close trading update
19th Jun 20125:05 pmRNSHolding(s) in Company
25th Apr 20127:00 amRNSInterim Results
2nd Apr 20127:00 amRNSAvacta Signs Exclusive Supply Deal with IDEXX
15th Mar 20127:00 amRNSNotice of Interim Results
24th Jan 201210:39 amRNSResult of AGM
19th Jan 20126:23 pmRNSHolding(s) in Company
12th Jan 201211:12 amRNSHolding(s) in Company
10th Jan 20129:26 amRNSCompletes £5.13m placing and Aptuscan acquisition
9th Jan 20124:10 pmRNSResults of General Meeting
22nd Dec 20117:00 amRNSConditional Placing and Proposed Acquisition
8th Dec 20112:20 pmRNSNotice of AGM and Report and Accounts
25th Nov 20117:00 amRNSAdditional Listing & Total Voting Rights
25th Oct 20117:00 amRNSPreliminary Results
21st Oct 20117:00 amRNSAppointment of Nomad and Broker
5th Oct 20117:00 amRNSSouth East Asian Alliance agreed with Pall
19th Sep 20117:00 amRNSNotice of Preliminary Results
9th Aug 20117:00 amRNSPre-close Trading Update
6th Jul 20117:00 amRNSChange of Registered Office
10th Jun 201112:50 pmRNSDirector/PDMR Shareholding
31st May 20117:00 amRNSAvacta secures second Optim sale in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.